Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.IM06wodO.js ...

[31] Simvastatin produced a 25% reduction in stroke occurrence without ... Management of ATherothrombosis with Clopidogrel in High-risk patients (MATCH) is presently comparing clopidogrel plus ...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, ...

Continuous acoramidis use resulted in a 48.2% reduction in relative risk of all-cause mortality or recurrent cardiovascular hospitalizations through 42 months. The FDA approved acoramidis for ATTR ...